Latest Insider Transactions at Nektar Therapeutics (NKTR)
This section provides a real-time view of insider transactions for Nektar Therapeutics (NKTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEKTAR THERAPEUTICS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEKTAR THERAPEUTICS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+24.71%
|
-
|
|
Aug 15
2022
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+36.85%
|
-
|
|
Aug 15
2022
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+33.0%
|
-
|
|
Aug 15
2022
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
410,625
+28.47%
|
-
|
|
May 16
2022
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,592
-2.02%
|
$13,776
$3.95 P/Share
|
|
May 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,136
-2.59%
|
$9,408
$3.95 P/Share
|
|
May 16
2022
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
17,448
-5.28%
|
$52,344
$3.95 P/Share
|
|
May 16
2022
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
36,529
-5.56%
|
$109,587
$3.95 P/Share
|
|
May 16
2022
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,841
-3.31%
|
$17,523
$3.95 P/Share
|
|
May 16
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
21,673
-7.27%
|
$65,019
$3.95 P/Share
|
|
May 15
2022
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
28,750
+8.01%
|
-
|
|
May 15
2022
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,450
+9.43%
|
-
|
|
May 15
2022
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,950
+5.85%
|
-
|
|
May 15
2022
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,950
+7.44%
|
-
|
|
Feb 16
2022
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
7,579
-2.45%
|
$75,790
$10.95 P/Share
|
|
Feb 16
2022
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,852
-2.09%
|
$48,520
$10.95 P/Share
|
|
Feb 16
2022
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
12,480
-2.07%
|
$124,800
$10.95 P/Share
|
|
Feb 16
2022
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,363
-1.41%
|
$23,630
$10.95 P/Share
|
|
Feb 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,661
-2.94%
|
$36,610
$10.95 P/Share
|
|
Feb 16
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
10,912
-3.83%
|
$109,120
$10.95 P/Share
|
|
Dec 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
52,950
+14.62%
|
-
|
|
Dec 16
2021
|
John Northcott SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,800
+13.98%
|
-
|
|
Dec 16
2021
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
126,050
+17.33%
|
-
|
|
Dec 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,200
+11.22%
|
-
|
|
Dec 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,800
+23.26%
|
-
|
|
Dec 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,950
+15.67%
|
-
|
|
Nov 18
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
3,000
-1.16%
|
$36,000
$12.69 P/Share
|
|
Nov 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
21,149
-7.53%
|
$274,937
$13.16 P/Share
|
|
Nov 16
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,061
-3.02%
|
$78,793
$13.16 P/Share
|
|
Nov 16
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
42,773
-8.25%
|
$556,049
$13.16 P/Share
|
|
Nov 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,741
-4.41%
|
$87,633
$13.16 P/Share
|
|
Nov 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,564
-7.06%
|
$85,332
$13.16 P/Share
|
|
Nov 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
20,869
-8.25%
|
$271,297
$13.16 P/Share
|
|
Nov 15
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,150
+12.51%
|
-
|
|
Nov 15
2021
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,100
+15.37%
|
-
|
|
Nov 15
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,900
+8.89%
|
-
|
|
Nov 15
2021
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+17.77%
|
-
|
|
Nov 15
2021
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,150
+13.7%
|
-
|
|
Nov 11
2021
|
Diana Brainard Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,360
+50.0%
|
-
|
|
Nov 09
2021
|
R Scott Greer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+4.09%
|
$150,000
$12.8 P/Share
|
|
Sep 22
2021
|
Jeffrey Robert Ajer Director |
SELL
Open market or private sale
|
Direct |
3,665
-10.13%
|
$62,305
$17.78 P/Share
|
|
Sep 22
2021
|
Jeffrey Robert Ajer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+21.99%
|
-
|
|
Sep 22
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
4,600
-1.62%
|
$78,200
$17.94 P/Share
|
|
Sep 22
2021
|
Robert Chess |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.46%
|
-
|
|
Sep 22
2021
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
3,665
-12.45%
|
$62,305
$17.78 P/Share
|
|
Sep 22
2021
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+25.73%
|
-
|
|
Sep 22
2021
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+22.92%
|
-
|
|
Sep 22
2021
|
R Scott Greer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.5%
|
-
|
|
Sep 22
2021
|
Roy A Whitfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+4.14%
|
-
|
|
Sep 16
2021
|
Roy A Whitfield Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.05%
|
$520,000
$13.8 P/Share
|